Database Commons
Database Commons

a catalog of worldwide biological databases

Database Profile

HBVrt DB

General information

URL: http://hivdb.stanford.edu/HBV/releaseNotes
Full name: HBV RT drug resistance database
Description: HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references.
Year founded: 2010
Last update: 2012
Version:
Accessibility:
Accessible
Country/Region: United States

Classification & Tag

Data type:
Data object:
Database category:
Major species:
Keywords:

Contact information

University/Institution: Stanford University
Address:
City:
Province/State:
Country/Region: United States
Contact name (PI/Team): Robert W.Shafer
Contact email (PI/Helpdesk): rshafer@stanford.edu

Publications

20875460
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. [PMID: 20875460]
Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, Verheyen J, Kaiser R, Shafer RW.

Drug resistance resulting from reverse transcriptase (RT) mutations is one of the main obstacles to successful hepatitis B virus (HBV) therapy. Indeed, HBV treatment guidelines recommend HBV genotypic resistance testing for patients receiving nucleos(t)ide RT inhibitors (N(t)RTIs) who develop virological failure. N(t)RTI-resistance mutations at 10 RT positions have been well characterized in phenotypic studies, however, data are lacking on the relative frequency of these mutations in N(t)RTI-treated and untreated individuals. There are also few published data on the extent of amino acid variation at most of the 344 positions of HBV RT and the extent to which this variation is influenced by N(t)RTI treatment. We retrieved 23,871 HBV RT sequences from GenBank and reviewed the published reports of these sequences to ascertain the number of individuals from whom the sequences were obtained, the N(t)RTI treatments of these individuals, and the year and region of virus sampling. We then used these data to populate a relational database we named HBVrtDB. As of July 2010, HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references. Among these 3869 individuals, 73% were N(t)RTI-naïve and 27% received one or more N(t)RTIs. Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly associated with treatment with lamivudine, an l-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate. A similar analysis of ten additional less well-characterized resistance mutations demonstrated a significant association with N(t)RTI treatment for four of the mutations: L82M, S85A, A200V, and Q215S. We also created an interactive program, HBVseq, to enable users to identify mutations in submitted sequences and retrieve the prevalence of these mutations in HBVrtDB according to genotype and N(t)RTI treatment. HBVrtDB and HBVseq are available at http://hivdb.stanford.edu/HBV/releaseNotes/.

Antiviral Res. 2010:88(3) | 41 Citations (from Europe PMC, 2025-12-13)

Ranking

All databases:
3492/6895 (49.369%)
Health and medicine:
875/1738 (49.712%)
3492
Total Rank
41
Citations
2.733
z-index

Community reviews

Not Rated
Data quality & quantity:
Content organization & presentation
System accessibility & reliability:

Word cloud

Related Databases

Citing
Cited by

Record metadata

Created on: 2018-01-28
Curated by:
Yang Zhang [2018-02-22]